Blood brain barrier-brain glioma organ chip as well as preparation method and application thereof

By simulating the blood-brain barrier and brain tumor microenvironment on a microfluidic chip, using ultrasound and multifunctional nanomicrobials, the problem of blood-brain barrier restriction treatment effect is solved, and an accurate research platform for brain glioma treatment is provided. Improves predictability of treatment effects.

CN118956598AInactive Publication Date: 2024-11-15NINGBO INST OF LIFE & HEALTH IND UNIV OF CHINESE ACAD OF SCI
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202411041422.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing treatment methods for brain glioma are limited by the blood-brain barrier, and chemotherapy drugs are difficult to effectively enter the brain parenchyma, resulting in poor treatment effects. The existing research models cannot accurately simulate the microenvironment of the human brain, resulting in poor drug screening results. precise.

Method used

Using microfluidic technology to design the blood-brain barrier-brain glioma organ chip, simulate the blood-brain barrier and brain tumor microscopy by inoculating astrocytes, brain microvascular endothelial cells and brain glioma cells on the microfluidic chip. and the treatment effect is evaluated using ultrasound collaborative multifunctional nanomicrobials.

Benefits of technology

A bionic system of brain glioma that is closer to the human disease state is established, which can simulate and predict the response characteristics of brain glioma patients to acoustic dynamic treatment, providing a new research platform for the precise treatment of brain glioma and improving Predictability of therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956598A_ABST
    Figure CN118956598A_ABST
Patent Text Reader

Abstract

The invention provides a blood brain barrier-brain glioma organ chip as well as a preparation method and application thereof, and relates to the technical field of organ chips. The preparation method comprises the following steps: designing a microfluidic channel structure template with three parallel channels; manufacturing a chromium plate mask according to the template, spin-coating negative photoresist on a blank silicon wafer, fixing the chromium plate mask on the silicon wafer for exposure, taking the silicon wafer, heating, cooling, developing and cleaning to manufacture a complete channel, and drying; pDMS is poured into a micro-fluidic chip mold, the chip is taken out after curing, and after ethanol soaking and water washing, punching is conducted, and the chip is bonded with a glass slide; astroglia cells are inoculated in the middle channel of the micro-fluidic chip, and brain microvascular endothelial cells and brain glioma cells are respectively inoculated in the two side channels of the micro-fluidic chip. The brain glioma-blood brain barrier organ chip model is established for the first time on the basis of the microfluidic technology and used for simulating the brain blood brain barrier and brain tumor microenvironment, and a new research platform is provided for precise treatment of brain glioma.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the technical field of organ chips, and in particular, to a blood-brain barrier-glioma organ chip and a preparation method and use thereof. Background Art

[0002] Gliomas are the most common primary tumors of the central nervous system, accounting for about 40-50% of central nervous system tumors. They are difficult to cure, have high recurrence rates, and have high mortality rates. According to the World Health Organization, there are about 500,000 new cases of gliomas worldwide each year, of which about 20,000 die. Due to its high invasiveness and recurrence rate, the average survival of patients is about 1-1.5 years, and the proportion of patients surviving for more than 5 years is less than 5%. At present, the treatment of gliomas is still mainly surgical resection and radiotherapy and chemotherapy. Although radiotherapy and chemotherapy are the main auxiliary treatment methods, due to limited targeting, they will inevitably affect normal brain tissue and have serious side effects on brain function. In addition, the brain tumor microenvironment is composed of tumor cells, extracellular matrix (ECM), various cytokines and blood-brain barrier (BBB), which is an internal environment that maintains the growth of tumor cells. It is a complex and dynamic microsystem in the body. Among them, due to the existence of the blood-brain barrier, most chemotherapy drugs cannot effectively enter the brain parenchyma, thus limiting the effect of radiotherapy and chemotherapy on brain gliomas.

[0003] The biggest challenge in chemotherapy for glioma is the blood-brain barrier, which is the barrier between the capillary wall of brain tissue and brain cells, and the barrier between plasma and cerebrospinal fluid formed by the choroid. Compared with common endothelial cells, the endothelial cells of the blood-brain barrier are tightly connected, and their biological function is mainly to maintain the energy supply and microenvironment homeostasis in brain tissue, and protect the central nervous system from infectious diseases and neurotoxins. While restricting the entry of substances into brain tissue to maintain homeostasis, the blood-brain barrier also becomes a natural obstacle for some drug molecules to enter the brain. Therefore, studying the blood-brain barrier is of great significance for the effective delivery of brain drugs. At present, most of the research on the blood-brain barrier is based on animal models and cell models. Although animal models can well reproduce the physiological environment of the human blood-brain barrier, its biggest limitation is genetic heterogeneity. This different genetic information may lead to incorrect drug screening results. The classic Transwell model can provide high-throughput and reproducible research tools, but it is difficult to reproduce the complex physiological environment of the brain (cell / cell, cell / extracellular matrix interactions and fluid shear force) The effect on the blood-brain barrier. Therefore, it is urgent to develop a new blood-brain barrier research platform that can simulate the human brain microenvironment. Summary of the invention

[0004] In order to solve the current shortage of brain glioma organ chips, the purpose of this application is to provide a blood-brain barrier-brain glioma organ chip and its preparation method. The organ chip can simulate the human blood-brain barrier and the complex brain tumor microenvironment, providing a new platform for the precision treatment of brain glioma.

[0005] The technical solution adopted in this application:

[0006] On the one hand, the present application provides a method for preparing a blood-brain barrier-glioma organ chip, comprising the following steps:

[0007] S1. Design a microfluidic channel structure template with three parallel channels, in which the middle channel and two side channels are separated by multiple trapezoidal microcolumns;

[0008] S2, making a chrome mask according to the microfluidic channel structure template in S1, spin-coating a negative photoresist on a blank silicon wafer, and then fixing the chrome mask on the silicon wafer for exposure, and then taking the silicon wafer for heating, cooling, developing and cleaning to make a complete channel, and drying to obtain a microfluidic chip template;

[0009] S3, pouring PDMS into the microfluidic chip mold, taking out the chip after curing, soaking it in ethanol and rinsing it with water, punching it and bonding it to a glass slide to obtain a microfluidic chip;

[0010] S4. Astrocytes are inoculated in the middle channel of the microfluidic chip, and brain microvascular endothelial cells and glioma cells are inoculated in the two side channels respectively, to obtain the blood-brain barrier-glioma organ chip.

[0011] On the other hand, the present application provides a blood-brain barrier-glioma organ chip prepared by the above-mentioned preparation method.

[0012] On the other hand, the present application provides an application of a blood-brain barrier-glioma organ chip in the field of glioma disease treatment research.

[0013] Microfluidics, also known as Lab on a chip, can integrate the basic operation steps such as cell culture, lysis and detection involved in conventional biology and chemistry into a chip of a few square centimeters or even smaller. The micro-nanoscale channels are interconnected to form a network, and the controllable fluid runs through the entire system to achieve various functions required by conventional biological or chemical experiments. In addition, microfluidics is widely used in the bionics of in vitro tissues and organs and the simulation of tumor microenvironments due to its advantages such as matching the micro-nanoscale with the cell size, the sealed culture method is closer to the physiological environment, and the fluid can perform controllable mechanical stimulation on cells. Organ chips were first proposed by Michael L. Shuler and others to use chips to construct and simulate the human tissue microenvironment. In 2010, Ingber's team successfully constructed a lung organ chip. They cultured lung epithelial cells and endothelial cells on both sides of the polydimethylsiloxane (PDMS) film in the microfluidic chip, and simulated the process of human alveolar inspiration / expiration by giving the interface periodic mechanical stimulation. It is the optimal model of the physiological function of lung organs in vitro. From then on, organ chips began a revolutionary development, and a large number of organ chips emerged, such as intestine chips, liver chips, brain chips, kidney chips, etc.

[0014] Compared with the prior art, the embodiments of the present application have at least the following advantages or beneficial effects:

[0015] This application establishes a glioma-blood-brain barrier organ chip model for the first time based on microfluidic technology to simulate the brain blood-brain barrier and brain tumor microenvironment. Using this model, the effect of ultrasound-assisted multifunctional nano-micelles in treating glioma can be evaluated.

[0016] This application establishes a bionic system for glioma that is closer to the disease state of the human body through cross-disciplinary microengineering, materials science, and cell biology. It promotes the instantaneous and reversible opening of the blood-brain barrier through ultrasonic cavitation, highly simulates and predicts the response characteristics of glioma patients to sonodynamic therapy, and provides a new research platform for the precision treatment of glioma. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present application and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0018] Figure 1 This is the blood-brain barrier-glioma organ chip diagram of Example 1 of this application, wherein Figure 1 a is the CAD schematic and dimension diagram of the organ chip. Figure 1 b is a 3D schematic diagram of the organ chip. Figure 1 c is a diagram showing the cell seeding of the organ chip;

[0019] Figure 2 This is the immunofluorescence staining image of the organ chip in Experimental Example 1 of this application, where Figure 2 a is the result of immunofluorescence staining. Figure 2 b is the fluorescence 3D image and xz, yz projection images of the endothelial channel (scale bar: 50 μm);

[0020] Figure 3 This is the live and dead staining image of endothelial channel cells in Experimental Example 1 of this application (scale 4X: 200μm, 10X: 50μm);

[0021] Figure 4 This is the result diagram of organ chip permeability in Experimental Example 2 of this application, where Figure 4 a is the FITC-dextran penetration fluorescence image within 60 minutes, Figure 4 b is the permeability bar graph of different penetration times (scale: 200 μm);

[0022] Figure 5 This is a diagram showing the effect of ultrasound on the blood-brain barrier in Experimental Example 3 of this application, where Figure 5 a represents the penetration image and permeability of 40KDa FITC-dextran after treatment with different ultrasonic powers; Figure 5 b is a 3D image of blood-brain barrier immunofluorescence staining of the organ chip after treatment with different ultrasound powers and one day of recovery (scale bar: 200 μm);

[0023] Figure 6 This is the situation of nanomicelles infiltrating into U87 cells at different time periods after injection in Experimental Example 4 of the present application (scale: 50 μm);

[0024] Figure 7 This is a live-dead staining image of U87 cells co-incubated for 1 day after ultrasound in Experimental Example 5 of the present application (scale bar: 50 μm). DETAILED DESCRIPTION

[0025] In order to make the purpose, technical scheme and advantages of the embodiments of the present application clearer, the technical scheme in the embodiments of the present application will be described clearly and completely below. If the specific conditions are not specified in the embodiments, they are carried out according to the conventional conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0026] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application can be combined with each other. The present application will be described in detail below with reference to specific embodiments.

[0027] A method for preparing a blood-brain barrier-glioma organ chip comprises the following steps:

[0028] S1. Design a microfluidic channel structure template with three parallel channels, in which the middle channel and two side channels are separated by multiple trapezoidal microcolumns;

[0029] S2, making a chrome mask according to the microfluidic channel structure template in S1, spin-coating a negative photoresist on a blank silicon wafer, and then fixing the chrome mask on the silicon wafer for exposure, and then taking the silicon wafer for heating, cooling, developing and cleaning to make a complete channel, and drying to obtain a microfluidic chip template;

[0030] S3, pouring PDMS into the microfluidic chip mold, taking out the chip after curing, soaking it in ethanol and rinsing it with water, punching it and bonding it to a glass slide to obtain a microfluidic chip;

[0031] S4. Astrocytes are inoculated in the middle channel of the microfluidic chip, and brain microvascular endothelial cells and glioma cells are inoculated in the two side channels respectively, to obtain the blood-brain barrier-glioma organ chip.

[0032] In some embodiments of the present application, in the above step S1, the width of the middle channel is 1200-1300 μm, the width of the two side channels is 900-1000 μm, and the height of the channel is 100-120 μm.

[0033] In some embodiments of the present application, the upper base of the trapezoidal microcolumn is 99 μm, the lower base is 330 μm, the height is 200 μm, and the distance between adjacent trapezoidal microcolumns is 200 μm.

[0034] In some embodiments of the present application, the spin coating of the negative photoresist in the above S2 step is specifically as follows: 500 rpm, 10 s in the first stage, 2500 rpm, 90 s in the second stage; then baked at 95°C for 1800 s and cooled; and the steps are repeated until the height reaches 100-120 μm.

[0035] In some embodiments of the present application, the ultraviolet light intensity of the exposure in step S2 is (95-105)×100 μW / cm 2 , exposure for 10s; heating is first 65℃, 10s, then 95℃, 300s; developing time is 4-6min; drying temperature is 200℃, and drying time is 1-2h.

[0036] In some embodiments of the present application, the PDMS in the above-mentioned S3 step is prepared by mixing its prepolymer and cross-linking agent in a mass ratio of 10:1 for 30 minutes; the curing temperature is 65°C, and the curing time is 1.5-2h; the ethanol immersion uses 75% ethanol, and the immersion time is 30min.

[0037] In some embodiments of the present application, the ratio of astrocytes in the above step S4 is 2.5×10 6 -3×10 6 cells / mL, which were inoculated into the middle channel and solidified at 37°C for 0.5 h; the inoculation ratio of brain microvascular endothelial cells was 2×10 6 -3×10 6 cells / mL, placed on its side for 0.5h after inoculation and then inoculated again, cultured for 2 days after two inoculations; the inoculation ratio of brain glioma cells was 2×10 6 -3×10 6 cells / mL.

[0038] A blood-brain barrier-glioma organ chip prepared by the above preparation method can be used in the field of glioma disease treatment research.

[0039] The features and performance of the present application are further described in detail below in conjunction with the embodiments.

[0040] Example 1

[0041] A blood-brain barrier-glioma organ chip, such as Figure 1 As shown, it is prepared by the following method:

[0042] S1. A microfluidic channel structure with three parallel channels was designed using AutoCAD software. The middle channel was used to seed astrocytes, and the two side channels were used to seed brain microvascular endothelial cells and glioma cells, respectively. The specific dimensions of the microfluidic channel structure are as follows: Figure 1 As shown in a, the 3D schematic diagram is Figure 1 As shown in b, the side channel width is 900 μm, the middle channel width is 1200 μm, the channel height of the manufactured microfluidic chip is 100 μm, the upper base of the trapezoidal micro-column structure between the middle channel and the two side channels is 99 μm, the lower base is 330 μm, the height is 200 μm, the micro-column spacing is 200 μm, and the micro-column structure provides a scaffold for 3D cell culture.

[0043] S2. Design the template designed in AutoCAD into a chrome mask of the same size for later use. Place a blank silicon wafer on the tray of the glue spreader, slowly add 15mL of SU-8 glue in the center of the silicon wafer, and then spin the glue at 500rpm, 10s in the first stage, and 2500rpm, 90s in the second stage. After spinning the glue, place the silicon wafer on a 95℃ hot plate and bake it for 1800s, remove it and let it cool, and measure the height. Repeat the above steps until the channel height reaches 100μm, and then expose it. Before exposure, adjust the UV light intensity of the photolithography machine to 95×100μW / cm 2 After fixing the chrome mask and silicon wafer, expose for 10 seconds, remove the silicon wafer, and place it on a hot plate for baking at 65℃, 10 seconds and 95℃, 300 seconds respectively. After cooling, use developer to quickly develop for 4 minutes, terminate the development with isopropanol, wash with pure water, blow dry, and observe whether the channel on the silicon wafer is complete under a microscope. If it is not complete, repeat the development. After confirming that the channel is complete, place the prepared template in a 200℃ oven for 1 hour to strengthen the bonding between SU-8 glue and the silicon wafer surface, and obtain a microfluidic chip template.

[0044] S3. Mix the PDMS prepolymer and crosslinker at a ratio of 10:1 (w / w). After mixing in a mixer for 30 minutes, pour the mixture evenly onto the pre-made template, use a vacuum pump to degas and remove bubbles, and place the degassed chip in a 65°C oven for 2 hours. After curing, cut with a utility knife and slowly peel off the chip, soak it in 75% ethanol for 30 minutes, then rinse with pure water, blow dry, punch holes in the liquid inlet and outlet holes with a 2mm hole puncher and bond it to a glass slide to obtain a microfluidic chip.

[0045] S4. Adjust the ratio of astrocytes (AC) to 2.5×10 6 cells / mL, mixed with matrix gel at a ratio of 3:5, seeded into the middle channel and solidified in a 37°C incubator for half an hour. The ratio of brain microvascular endothelial cells (HCMECs) was adjusted to 2×10 6 cells / mL, inoculated into the side channel, and placed sideways for half an hour before repeating the inoculation. After the two cell types were co-cultured for 2 days, the ratio of brain glioma cells (U87) was adjusted to 2×10 6 cell / mL, inoculated to the other channel, the inoculation situation is as follows Figure 1 As shown in c.

[0046] Example 2

[0047] A blood-brain barrier-glioma organ chip, the preparation method of which is as follows:

[0048] S1. A three-channel parallel microfluidic channel structure was designed using AutoCAD software, in which the middle channel was used to seed astrocytes, and the two side channels were used to seed brain microvascular endothelial cells and glioma cells, respectively. The side channel width was 1000μm, the middle channel width was 1300μm, the channel height of the microfluidic chip was 120μm, the upper base of the trapezoidal microcolumn structure between the middle channel and the two side channels was 99μm, the lower base was 330μm, the height was 200μm, the microcolumn spacing was 200μm, and the microcolumn structure provided a scaffold for 3D cell culture.

[0049] S2. Design the template designed in AutoCAD into a chrome mask of the same size for later use. Place a blank silicon wafer on the tray of the glue spreader, slowly add 20mL of SU-8 glue in the center of the silicon wafer, and then spin the glue at 500rpm, 10s in the first stage, and 2500rpm, 90s in the second stage. After spinning the glue, place the silicon wafer on a 95℃ hot plate and bake it for 1800s, remove it and let it cool, and measure the height. Repeat the above steps until the channel height reaches 100μm, and then expose it. Before exposure, adjust the UV light intensity of the photolithography machine to 100×100μW / cm 2 After fixing the chrome mask and silicon wafer, expose for 10 seconds, remove the silicon wafer, and place it on a hot plate for baking at 65℃, 10 seconds and 95℃, 300 seconds respectively. After cooling, use developer to quickly develop for 4 minutes, terminate the development with isopropanol, wash with pure water, blow dry, and observe whether the channel on the silicon wafer is complete under a microscope. If it is not complete, repeat the development. After confirming that the channel is complete, place the prepared template in a 200℃ oven for 1 hour to strengthen the bonding between SU-8 glue and the silicon wafer surface, and obtain a microfluidic chip template.

[0050] S3. Mix the PDMS prepolymer and crosslinker at a ratio of 10:1 (w / w). After mixing in a mixer for 30 minutes, pour the mixture evenly onto the pre-made template, use a vacuum pump to degas and remove bubbles, and place the degassed chip in a 65°C oven for curing for 1.5 hours. After curing, cut with a utility knife and slowly peel off the chip, soak it in 75% ethanol for 30 minutes, then rinse with pure water, blow dry, punch holes in the liquid inlet and outlet holes with a 2mm hole puncher and bond it to the glass slide to obtain a microfluidic chip.

[0051] S4. Adjust the ratio of astrocytes (AC) to 2.5×10 6 cells / mL, mixed with matrix gel at a ratio of 3:5, seeded into the middle channel and solidified in a 37°C incubator for half an hour. The ratio of brain microvascular endothelial cells (HCMECs) was adjusted to 2×10 6cells / mL, inoculated into the side channel, and placed sideways for half an hour before repeating the inoculation. After the two cell types were co-cultured for 2 days, the ratio of brain glioma cells (U87) was adjusted to 2×10 6 cell / mL and inoculated into the other side channel to obtain the blood-brain barrier-glioma organ chip.

[0052] Example 3

[0053] A blood-brain barrier-glioma organ chip, the preparation method of which is as follows:

[0054] S1. A three-channel parallel microfluidic channel structure was designed using AutoCAD software, in which the middle channel was used to inoculate astrocytes, and the two side channels were used to inoculate brain microvascular endothelial cells and brain glioma cells, respectively. The width of the side channel was 1000μm, the width of the middle channel was 1300μm, the height of the microfluidic chip channel was 100μm, the upper base of the trapezoidal microcolumn structure between the middle channel and the two side channels was 99μm, the lower base was 330μm, the height was 200μm, the microcolumn spacing was 200μm, and the microcolumn structure provided a scaffold for 3D cell culture.

[0055] S2. Design the template designed in AutoCAD into a chrome mask of the same size for later use. Place a blank silicon wafer on the tray of the glue spreader, slowly add 10mL of SU-8 glue in the center of the silicon wafer, and then spin the glue at 500rpm, 10s in the first stage, and 2500rpm, 90s in the second stage. After spinning the glue, place the silicon wafer on a 95℃ hot plate and bake it for 1800s, remove it and let it cool, and measure the height. Repeat the above steps until the channel height reaches 100μm, and then expose it. Before exposure, adjust the UV light intensity of the photolithography machine to 105×100μW / cm 2 After fixing the chrome mask and silicon wafer, expose for 10 seconds, remove the silicon wafer, and place it on a hot plate for baking at 65℃, 10 seconds and 95℃, 300 seconds respectively. After cooling, use developer to quickly develop for 5 minutes, terminate the development with isopropanol, wash with pure water, blow dry, and observe whether the channel on the silicon wafer is complete under a microscope. If it is not complete, repeat the development. After confirming that the channel is complete, place the prepared template in a 200℃ oven for 1 hour to strengthen the bonding between SU-8 glue and the silicon wafer surface, and obtain a microfluidic chip template.

[0056] S3. Mix the PDMS prepolymer and crosslinker at a ratio of 10:1 (w / w). After mixing in a mixer for 30 minutes, pour the mixture evenly onto the pre-made template, use a vacuum pump to degas and remove bubbles, and place the degassed chip in a 65°C oven for 2 hours. After curing, cut with a utility knife and slowly peel off the chip, soak it in 75% ethanol for 30 minutes, then rinse with pure water, blow dry, punch holes in the liquid inlet and outlet holes with a 2mm hole puncher and bond it to a glass slide to obtain a microfluidic chip.

[0057] S4. Adjust the ratio of astrocytes (AC) to 3×10 6 cells / mL, mixed with matrix gel at a ratio of 3:5, seeded into the middle channel and solidified in a 37°C incubator for half an hour. The ratio of brain microvascular endothelial cells (HCMECs) was adjusted to 3×10 6 cells / mL, inoculated into the side channel, and repeated inoculation after half an hour of side placement. After the two cells were co-cultured for 2 days, the ratio of brain glioma cells (U87) was adjusted to 3×10 6 cell / mL and inoculated into the other side channel to obtain the blood-brain barrier-glioma organ chip.

[0058] Experimental Example 1

[0059] In this experimental example, the growth of cells in the blood-brain barrier-glioma organ chip prepared in Example 1 was detected.

[0060] 1. Immunofluorescence staining: Pipette the culture medium on the surface of the chip and wash it three times with PBS, each time for 5 minutes. Fix it with 4% paraformaldehyde at room temperature in the dark for 10 minutes, then wash it three times with PBS, each time for 5 minutes. Add 0.1% Triton X-100 to permeate for 15 minutes, then block it with 2% BSA at room temperature for 45 minutes, and wash it three times with PBST (PBS+0.1% Tween-20), each time for 5 minutes. Mix the tight junction protein ZO-1 antibody with 0.1% BSA solution at a ratio of 1:200, incubate at 4°C for 18 hours, and wash it three times with PBST, each time for 5 minutes. Mix the secondary antibody with 0.1% BSA solution at a ratio of 1:1000, incubate it at room temperature in the dark for 45 minutes, and wash it three times with PBST, each time for 5 minutes. Finally, add DAPI and incubate it at room temperature in the dark for 1 minute, wash it three times with PBST, each time for 5 minutes, remove the liquid on the surface of the chip, and observe the barrier construction with a laser confocal microscope. The results are as follows Figure 2 As shown, the ZO-1 staining results showed that tight junction proteins were stably expressed at the border of HCMECs, and the fluorescent 3D images showed that endothelial cells grew well on the side walls of the channel.

[0061] 2. Cell live and dead staining: Calcein (Calcein) increases its hydrophobicity after the introduction of acetyl methoxymethyl ester (AM), and can easily pass through the cell membrane. It is a cell staining reagent for fluorescent labeling of living cells and emits green fluorescence. Propidium iodide (PI) cannot pass through the cell membrane of living cells, but can only pass through the disordered area of ​​the dead cell membrane to reach the cell nucleus, and embed into the cell's DNA double helix to produce red fluorescence. Rinse the chip channel three times with 1x Assay Buffer, 5 minutes each time. Mix the Calcein-AM stock solution and 1x Assay Buffer at a ratio of 1:1000 and add them to the chip. Incubate at 37°C in the dark for 25 minutes. Add 1μL of PI solution to the above dye solution, mix and add to the chip. Incubate at room temperature in the dark for 5 minutes. Wash 3 times with PBS, 5 minutes each time, and observe the staining of HCMECs under a fluorescence microscope. The results are as follows: Figure 3 As shown, it indicates that the endothelial channel cells survive well.

[0062] Experimental Example 2

[0063] This experimental example detects the permeability function of the blood-brain barrier-glioma organ chip, and the organ chip is prepared by the method of Example 1.

[0064] FITC-dextran with a concentration of 100 μg / mL and 40 KDa was injected into the channel where HCMECs were grown, and the fluorescence intensity was calculated using Image J every 20 min, and the permeability was calculated. The calculation method is as follows:

[0065] P(cm / s)=(1 / (F 0 -F 1 ))x((F 2 -F 1 ) / (△t))xV / A

[0066] Among them, F 0 is the fluorescence intensity of the endothelial channel, F 1 is the fluorescence intensity of the middle channel at the initial time, F 2 is the fluorescence intensity of the middle channel after a period of penetration, V is the volume of the middle channel penetrated, and A is the surface area of ​​the side wall of the endothelial channel.

[0067] The results are as follows Figure 4 As shown, the penetration rates of 20 min, 40 min and 60 min were 2.01×10 -8 , 9.87×10 -9 and 4.22×10 -9cm / s. The permeation results showed that the permeability of 40KDa FITC-dextran was low, which was highly similar to that of rodents, indicating that the blood-brain barrier model in the chip was successfully constructed and could simulate the blood-brain barrier of the human brain microenvironment for research.

[0068] Experimental Example 3

[0069] This experimental example explores the effects of different ultrasonic powers on the blood-brain barrier of an organ chip, and the organ chip is prepared by the method of Example 1.

[0070] The medium containing 100 μg / mL 40KDa FITC-dextran was injected into the channel where HCMECs were grown. The cells were ultrasonically stimulated with different powers (1 W / cm 2 , 2W / cm 2 、3W / cm 2 ) The chip was ultrasonically treated at the bottom of the glass slide with a duty cycle of 60% and an ultrasonic time of 30 seconds. Fluorescence microscopy was used to observe the penetration of FITC-dextran to evaluate the openness of the blood-brain barrier at different ultrasound powers, and laser confocal microscopy was used to observe the recovery of the blood-brain barrier one day after ultrasound treatment. Figure 5 As shown, from Figure 5 It can be seen that 1W / cm 2 , 2W / cm 2 and 3W / cm 2 The penetration rates after 60 min of penetration were 4.43×10 -7 , 1.22×10 -6 and 2.81×10 -6 cm / s. Although the higher the ultrasonic power, the faster the penetration rate, the higher the ultrasonic power, the faster the penetration rate. 2 The blood-brain barrier was restored after one day of ultrasound treatment, so the ultrasound power was selected to be 1 W / cm 2 .

[0071] Experimental Example 4

[0072] This experimental example explores the targeted enrichment effect of nanomaterials on organ chips on brain gliomas, and the organ chip is prepared by the method of Example 1.

[0073] Preparation of nanomicelles: 10 mg / mL of amphipathic peptide C18GR7RGDS, 200 μg / mL of RB and 2 mM of sulforaphane (SFN) were prepared, and the prepared amphipathic peptide was ultrasonicated at 25°C and 40 kHz for 30 min. After the ultrasonication, the solution was transferred to a 1000 Da dialysis bag and dialyzed for 48 h. The water was changed every 4 h or so. The whole experiment was kept away from light. After the dialysis, the prepared nanomicelles were stored at 4°C in the dark.

[0074] Ultrasonication of the chip, the ultrasonic power is 1W / cm 2 After the ultrasound, the culture medium containing nano-micelles (10 μg / mL) was added to the endothelial channel immediately, and the entry of nano-micelles into the brain glioma was observed under a fluorescence microscope at different time periods to determine the optimal penetration time. Figure 6 As shown, the amount of nanomicelles penetrating into brain glioma reached a peak after 4 h.

[0075] Experimental Example 5

[0076] This experimental example explores the effect of evaluating sonodynamic therapy for glioma on a blood-brain barrier-glioma organ chip; the organ chip of this experimental example was prepared by the method of Example 1, and the nanomicelles were prepared by the method of Experimental Example 4.

[0077] The culture medium containing 10 μg / mL nanomicelles was added to the endothelial channel at 1 W / cm 2 The chip was ultrasonically treated with a power of 1 W / cm 2 The chip was ultrasonically treated again with a power of 1000. After culturing in a 37°C incubator for 1 day, the cells in the chip were stained for live and dead cells and observed under a fluorescence microscope. Figure 7 As shown, the results of cell live-death staining showed that most of the cells were dead cells (red), indicating that ultrasound combined with nano-micelles can have a strong killing effect on brain gliomas.

[0078] Through Experimental Examples 4 and 5, the present application explored a new strategy for treating brain glioma by using acoustic means combined with multifunctional nano-micelles, which can highly simulate and predict the response characteristics of brain glioma patients to sonodynamic therapy.

[0079] In summary, the blood-brain barrier-glioma organ chip and its preparation method and use in the embodiments of the present application have the following advantages:

[0080] This application establishes a glioma-blood-brain barrier organ chip model for the first time based on microfluidic technology, and establishes a medical bionic model of glioma to simulate the brain blood-brain barrier and brain tumor microenvironment. Using this model, we evaluate the effect of ultrasound-synergistic multifunctional nano-micelles in the treatment of glioma. The present invention establishes a bionic system of glioma that is closer to the disease state of the human body through cross-microengineering, material science, and cell biology. It promotes the instantaneous and reversible opening of the blood-brain barrier through ultrasonic cavitation, highly simulates and predicts the response characteristics of glioma patients to sonodynamic therapy, and provides a new research platform for the precision treatment of glioma.

[0081] The embodiments described above are part of the embodiments of the present application, rather than all of the embodiments. The detailed description of the embodiments of the present application is not intended to limit the scope of the present application for protection, but merely represents the selected embodiments of the present application. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without making creative work belong to the scope of protection of the present application.

Claims

1. A method for preparing a blood-brain barrier-glioma organ chip, It is characterized in that The following steps are involved: S1. Design a microfluidic channel structure template with three parallel channels, in which the middle channel and two side channels are separated by multiple trapezoidal microcolumns; S2, making a chrome mask according to the microfluidic channel structure template in S1, spin-coating a negative photoresist on a blank silicon wafer, and then fixing the chrome mask on the silicon wafer for exposure, and then taking the silicon wafer for heating, cooling, developing and cleaning to make a complete channel, and drying to obtain a microfluidic chip template; S3, pouring PDMS into the microfluidic chip mold, taking out the chip after curing, soaking it in ethanol and rinsing it with water, punching it and bonding it to a glass slide to obtain a microfluidic chip; S4. Astrocytes are inoculated in the middle channel of the microfluidic chip, and brain microvascular endothelial cells and glioma cells are inoculated in the two side channels respectively, to obtain the blood-brain barrier-glioma organ chip.

2. A method for preparing a blood-brain barrier-glioma organ chip according to claim 1, It is characterized in that In the S1 step, the width of the middle channel is 1200-1300 μm, the width of the two side channels is 900-1000 μm, and the height of the channel is 100-120 μm.

3. The method for preparing a blood-brain barrier-glioma organ chip according to claim 1, It is characterized in that The upper base of the trapezoidal microcolumn is 99 μm, the lower base is 330 μm, the height is 200 μm, and the distance between adjacent trapezoidal microcolumns is 200 μm.

4. The method for preparing a blood-brain barrier-glioma organ chip according to claim 1, It is characterized in that The spin coating of the negative resist in step S2 is specifically as follows: the first stage is 500 rpm for 10 s, the second stage is 2500 rpm for 90 s; then it is baked at 95° C. for 1800 s and cooled; and the steps are repeated until the height reaches 100-120 μm.

5. A method for preparing a blood-brain barrier-glioma organ chip according to claim 4, It is characterized in that The ultraviolet light intensity of the exposure in step S2 is (95-105)×100 μW / cm 2 , exposure for 10s; heating is first 65℃, 10s, then 95℃, 300s; developing time is 4-6min; drying temperature is 200℃, and drying time is 1-2h.

6. The method for preparing a blood-brain barrier-glioma organ chip according to claim 1, It is characterized in that In the step S3, the PDMS is prepared by mixing the prepolymer and the cross-linking agent at a mass ratio of 10:1 for 30 minutes; the curing temperature is 65° C. and the curing time is 1.5-2 hours; and the ethanol immersion uses 75% ethanol for 30 minutes.

7. The method for preparing a blood-brain barrier-glioma organ chip according to claim 1, It is characterized in that The ratio of astrocytes in the S4 step is 2.5×10 6 -3×10 6 cells / mL, which were inoculated into the middle channel and solidified at 37°C for 0.5 h; the inoculation ratio of brain microvascular endothelial cells was 2×10 6 -3×10 6 cells / mL, placed on its side for 0.5h after inoculation and then inoculated again, cultured for 2 days after two inoculations; the inoculation ratio of brain glioma cells was 2×10 6 -3×10 6 cells / mL.

8. A blood-brain barrier-glioma organ chip, It is characterized in that The method is prepared by any one of claims 1 to 7.

9. Application of the blood-brain barrier-glioma organ chip according to claim 8 in the field of glioma disease treatment research.

Citation Information

Patent Citations

  • Establishment and characterization method of in-vitro blood brain barrier model based on microfluidic chip

    CN102978109A

  • In-vitro construction method for simulating blood brain barrier through human brain microangiogenesis

    CN108823145A

  • Method for building three-dimensional analog brain development models on basis of micro-fluidic chips

    CN109082406A

  • Design method for dual-arch-bridge capillary passive valve based on cross section abrupt changing

    CN111378561A

  • Bionic micro-fluidic chip for simulating pathological blood-brain barrier based on fibrous protein gel and construction method of bionic micro-fluidic chip

    CN114181833A